Design, synthesis, and evaluation of chromone-triazole-thioether-benzoxazole hybrids as anti-diabetic and anti-oxidant agents with in silico, docking, simulation and DFT studies.
Abstract
Type 2 diabetes mellitus (T2DM) is a metabolic disorder associated with persistent hyperglycemia and impaired glucose regulation. Inhibition of pancreatic α-amylase is an important approach for reducing carbohydrate digestion and controlling postprandial blood glucose levels. In this study, a new series of substituted chromone-triazole-thioether-benzoxazole hybrid derivatives was designed and synthesized, and evaluated for their α-amylase inhibitory and antioxidant activities, supported by molecular docking and in silico ADMET and DFT studies. Docking studies identified 9 k as the most promising compound, with a CDOCKER interaction energy of -9.3 kcal/mol, compared with -8.6 kcal/mol for acarbose and - 8.4 kcal/mol for myricetin. Further molecular dynamics simulations and DFT studies were performed, which revealed the stability of 9 k complexes with α-amylase. The in vitro α-amylase assay showed that all compounds exhibited concentration-dependent inhibition. Among them, 9 k was the most potent inhibitor, with an IC50 value of 0.41 μg/mL, 0.98 μM, followed by 9 h (1.95 μg/mL, 4.15 μM), 9 l (2.89 μg/mL, 6.43 μM), 9n (3.25 μg/mL, 7.14 μM), and 9i (4.70 μg/mL, 11.62 μM). These compounds showed considerably stronger inhibition than the reference drug acarbose (IC₅₀ = 27.61 μg/mL, 42.77 μM). In the DPPH assay, 9 g showed the strongest radical-scavenging activity (IC₅₀ = 0.05 μg/mL, 0.11 μM), followed by 9a (0.62 μg/mL, 1.59 μM), 9i (1.34 μg/mL, 3.31 μM), and 9n (2.52 μg/mL, 5.54 μM). In silico ADME analysis indicated that most of the synthesized derivatives possessed acceptable drug-like and pharmacokinetic properties. Toxicity prediction further suggested a favorable safety profile. Overall, the combined biological and computational findings identified 9 k, and 9n as the most promising compounds, which may act as lead candidates for further development of novel antidiabetic agents.